A Peptide for Low Sexual Desire in Men. What a New Brain-Imaging Study of Kisspeptin Found

Most peptides are in a gray zone. They're interesting, but have little human data, no regulatory approval. Every so often, though, a peptide shows up in a top-tier medical journal with a properly designed human trial behind it. Kisspeptin is one of those, and a study published in JAMA Network Open is a good example of what real, careful peptide research looks like.

The headline finding: in men with low sexual desire, a naturally occurring peptide called kisspeptin measurably changed how their brains responded to sexual cues. It produced real physical and emotional effects compared to a placebo. Here's what that means, in plain terms, and why it matters relative to what came before.

The Problem This Study Was Trying to Solve

There's a condition called hypoactive sexual desire disorder (HSDD) which is persistently low sexual desire that causes personal distress. It's often assumed to be a women's issue, but it affects men too. This study notes it affects up to 8% of men, and here's the striking part: there are currently no approved medications to treat it in men, and nothing in development.

The drugs people assume would help mostly don't. Viagra and similar drugs (PDE5 inhibitors) work on the plumbing. But they don't affect desire itself. If the interest isn't there, improving blood flow doesn't fix the actual problem. And testosterone, the other obvious candidate, doesn't improve sexual function in men whose testosterone is already in the normal range. So a man with normal hormones and low desire has essentially no pharmaceutical option. That's the void this research is trying to fill.

What Kisspeptin Is

Kisspeptin is not an exotic designer compound. It's a peptide your own body produces, a natural signal that sits at the top of the reproductive hormone system. It helps kick off puberty, and it plays a role in regulating the downstream reproductive hormones throughout adult life.

What makes it interesting for this study is that kisspeptin doesn't just act on hormones, it acts on the brain directly. Its receptors show up in brain regions involved in attraction, arousal, motivation, and emotional processing. Earlier work by the same research group had already shown that in healthy men, kisspeptin could enhance the brain's response to sexual stimuli. This study asked the natural next question: would it help men who actually have a problem with low desire?

How the Study Was Done

It's worth noting the quality of the design, because it's the kind of testing that separates real evidence from anecdotes.

It was a randomized, double-blind, placebo-controlled crossover trial. In plain terms:

• Randomized and double-blind: Neither the participants nor the researchers analyzing the data knew who was getting kisspeptin versus placebo at any given visit. This is what guards against wishful thinking on both sides.
• Placebo-controlled: Every man was compared against a dummy infusion, so the real effects could be separated from the powerful placebo response that sexual-function studies are notorious for.
• Crossover: Each man received both kisspeptin and placebo on separate visits at least a week apart, in random order. This is a particularly clean design because every participant serves as his own comparison, removing a lot of the noise that comes from comparing different people.

Thirty-two men with HSDD completed the trial. While they received either kisspeptin or placebo through an IV, they watched sexual videos inside an fMRI scanner, a machine that maps brain activity in real time — while researchers simultaneously measured physical arousal and asked them about how they felt.

So the study captured three different layers at once: what the brain did, what the body did, and what the men subjectively experienced. That is what makes the findings persuasive.

What They Found

In the brain: Kisspeptin significantly changed activity in the network of brain regions that handle sexual processing. Two things happened that are worth understanding together. It boosted activity in regions involved in paying attention to and being motivated by sexual cues. And it quieted activity in regions involved in self-monitoring and self-focus.

That second part is subtle but important. Research on low sexual desire suggests that part of the problem is a kind of over-thinking. Attention gets pulled away from the sexual experience and toward internal self-monitoring, which shuts arousal down. What kisspeptin appeared to do was shift the balance: more attention on the sexual cue, less on the distracting internal chatter. The study frames this as dialing up the "go" signals while dialing down the brain's tendency to get in its own way.

In the body: Men showed significantly more physical arousal (measured objectively) in response to the sexual videos on kisspeptin than on placebo, up to 56% more by the end of the eight-minute video. This matters because it's not a subjective report that could be swayed by expectation; it's a physical measurement.

In how they felt: Perhaps the most human finding, kisspeptin significantly increased the men's self-reported happiness about sex compared to placebo. For a condition defined by distress around sex, an intervention that increases positive feeling about it is hitting close to the actual target.

On safety: Kisspeptin was well tolerated, with no side effects or adverse events reported, and no meaningful effects on blood pressure or heart rate. That clean tolerability profile makes sense given that it's a compound the body already produces.

Why This Matters Relative to What Came Before

To put the significance in context:

Before this study, the options for men with low desire and normal hormones were essentially nothing that addressed desire itself. Erection drugs miss the target. Testosterone doesn't help the normal-hormone group. There was no pharmacological strategy aimed at the desire part of the problem, and nothing in the pipeline.

What this study adds is the first clinical evidence, in men who actually have the disorder, that a compound can reach into the brain's sexual-processing network and shift it in a favorable direction. With the brain, body, and subjective findings all pointing the same way. The authors describe it as the first evidence that kisspeptin could offer a much-needed treatment strategy for men with low sexual desire.

There's also a nice piece of scientific symmetry here: the same research group had previously run a parallel trial in women with HSDD. So the kisspeptin approach is being investigated across both sexes by a team that has built up a decade of work on how this peptide affects the brain, which is a sign of a serious, sustained research program rather than a one-off finding.

The Limitations

It's a small study. Thirty-two men. That's an appropriate size for an intensive brain-imaging trial because those are expensive and complex, but it's far from the large trials needed to establish a treatment.

It was a single dose in a lab, not a treatment course. The men received kisspeptin via IV infusion during a scanning session. This tells us the compound can shift sexual brain processing. It does not tell us what happens if you take it regularly over weeks or months, whether the effect holds up, or whether it translates into a better sex life outside a laboratory. Those are different questions requiring different studies.

The participant group was narrow. By design, the study enrolled right-handed heterosexual men, to keep the sexual stimuli consistent across participants. Whether the findings generalize to other groups remains to be tested.

IV infusion isn't a practical treatment. Nobody's going to get an IV drip for this in real life. The encouraging news the authors note is that kisspeptin can be delivered by simpler routes: under the skin or via nasal spray, which is what future treatment-focused studies would need to use. But that work still has to be done.

So this is an early, high-quality proof-of-concept, strong evidence that the mechanism is real and worth pursuing. It's not evidence that a treatment is ready.

Summary

Kisspeptin is a good example of a peptide doing things the right way: a naturally occurring compound, a defined mechanism, and a carefully controlled human trial published in a major journal, showing effects across brain, body, and subjective experience simultaneously. That's a different evidence picture than most of what goes around in the peptide world.

What it isn't, yet, is a treatment. The path from "this shifts brain activity in a single lab session" to "here's a prescription" must go through larger trials, practical delivery methods, and longer follow-up. None of which has happened yet. Kisspeptin-based therapeutics for low sexual desire are a real and promising research direction, not something available at a pharmacy yet.

This article is for informational purposes only and is not medical advice. Kisspeptin is an investigational compound and is not an approved treatment for low sexual desire. If low sexual desire is causing you distress, a conversation with a qualified healthcare provider is the right starting point — the causes are varied, and several are treatable.